Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:associated_with |
gptkb:healthcare_organization
gptkb:municipality biomarker discovery clinical trials molecular diagnostics patient advocacy personalized medicine research funding targeted therapies disease progression treatment response genomic instability epigenetic changes genetic counseling angiogenesis combination therapies resistance to therapy poor prognosis family history of cancer immune evasion metabolic reprogramming increased cell survival therapeutic resistance mechanisms screening recommendations adverse effects of treatment long-term survival outcomes quality of life in patients tumor microenvironment alteration |
| gptkbp:clinical_trial |
biomarker for targeted therapy
|
| gptkbp:code |
gptkb:anaplastic_lymphoma_kinase_protein
|
| gptkbp:discovered_by |
gptkb:2007
|
| gptkbp:genetic_diversity |
gptkb:mythological_figure
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALK fusion gene
|
| gptkbp:influences |
tumor growth
metastasis |
| gptkbp:is_aimed_at |
gptkb:alectinib
gptkb:ceritinib gptkb:crizotinib |
| gptkbp:is_found_in |
gptkb:healthcare_organization
gptkb:neuroblastoma cancers with neuroendocrine features |
| gptkbp:is_involved_in |
apoptosis regulation
cell proliferation signal transduction pathways chromosomal rearrangement |
| gptkbp:is_recognized_by |
gptkb:healthcare_organization
PCR next-generation sequencing FISH analysis |
| gptkbp:research_areas |
oncology
molecular genetics |
| gptkbp:type_of |
inversion
translocation |
| gptkbp:bfsParent |
gptkb:anaplastic_large_cell_lymphoma,_ALK-positive
|
| gptkbp:bfsLayer |
6
|